MYC association with cancer risk and a new model of MYC-mediated repression

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 7, 2014, Pages

  Cole, Michael D ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB REPRESSIVE COMPLEX 2; TPTE PROTEIN, HUMAN;

ARTICLE; AUTOREGULATION; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMATIN; CHROMOSOME BAND; CHROMOSOME TRANSLOCATION; FEEDBACK SYSTEM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HISTONE MODIFICATION; HUMAN; NONHUMAN; ONCOGENE MYC; REGULATOR GENE; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; DNA METHYLATION; EPIGENETIC REPRESSION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; NEOPLASM; PHOSPHORYLATION; RISK FACTOR;

DNA METHYLATION; EPIGENETIC REPRESSION; GENES, MYC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEMBRANE PROTEINS; MODELS, GENETIC; MUTATION; NEOPLASMS; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 2; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; RISK FACTORS;

EID: 84891770537     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014316     Document Type: Article

References (59)

1. Adhikary S, Eilers M. 2005. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645.
2. Amundadottir IT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, et al. 2006. A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 652-658.
3. Bracken AP, Helin K. 2009. Polycomb group proteins: Navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9: 773-784.
4. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. 2003. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323-5335.
5. Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M. 1998. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev 12: 3797-3802.
6. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP, Hung MC. 2005. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in his-tone H3. Science 310: 306-310.
7. Chalhoub N, Baker SJ. 2009. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127-150.
8. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, Takata R, Akamatsu S, Kawaguchi T, Mori-zono T, et al. 2011. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Can-cerSci 102: 245-252.
9. Cory S, Graham M, Webb E, Corcoran L, Adams JM. 1985. Variant (6;15) translocations in murine plasmacytomas involve a chromosome 15 locus at least 72 kb from the c-myc oncogene. EMBO J 4: 675-681.
10. Cowling VH, Cole MD. 2006. Mechanism oftranscriptional activation by the Myc oncoproteins. Semin Cancer Biol 16: 242-252.
11. Cowling VH, Chandriani S, Whitfield ML, Cole MD. 2006. A conserved Myc protein domain, MBIV, regulates DNA binding, apoptosis, transformation, and G2 arrest. Mol Cell Biol 26: 4226-4239.
12. Curtin K, Lin WY, George R, Katory M, Shorto J, Cannon-Albright LA, Bishop DT, Cox A, Camp NJ. 2009. Meta association of colorectal cancer confirms risk alleles at 8q24 and 18q21. Cancer Epidemiol Biomarkers Prev 18: 616-621.
13. Dekker J. 2006. The three "C"s of chromosome conformation capture: Controls, controls, controls. Nat Methods 3:17-21.
14. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, et al. 2007. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
15. Facchini LM, Chen S, Marhin WW, Lear JN, Penn LZ. 1997. The Myc negative autoregulation mechanism requires Myc-Max association and involves the c-Myc P2 minimal. Mol Cell Biol 17: 100-114.
16. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. 2003. Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
17. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL. 2001. Myc represses the p21 WAFl/CIP1promoter and interacts with Sp1 /Sp3. Proc Natl Acad Sci 98:4510-4515.
18. Goodliffe JM, Wieschaus E, Cole MD. 2005. Polycomb mediates Myc autorepression and its transcriptional control of many loci in Drosophila. Genes Dev 19: 2941-2946.
19. Graham M, Adams JM, Cory S. 1985. Murine T lymphomas with retroviral inserts in the chromosomal 15 locus for plasmacytoma variant translocations. Nature 314: 740-743.
20. Grignani F, Lombardi L, Inghirami G, Sternas L, Cechova K, Dalla-Favera R. 1990. Negative autoregulation of c myc gene expression is inactivated in transformed cells. EMBO J 9: 3913-3922.
21. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafiiar T, Bergthorsson JT, Agnarsson BA, Baker A, et al. 2007. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39: 631-637.
22. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Dang CV, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, et al. 2008. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21:1156-1167.
23. Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M, Helin K. 2008. A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol 10: 1291-1300.
24. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
25. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, et al. 2007. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39: 311-318.
26. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, et al. 2009. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459:108-112.
27. Huppi K, Pitt JJ, Wahlberg BM, Caplen NJ. 2012. The 8q24 gene desert: An oasis of non-coding transcriptional activity. Front Genet 3: 69.
28. Jenkins RB, Qian J, Lieber MM, Bostwick DG. 1997. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57: 524-531.
29. Kaur M, Cole MD. 2013. MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression byactivation ofthe Ezh2 methyltransfer-ase. Cancer Res 73: 695-705.
30. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, Gudmundsson J, Jakobsdottir M, Bergthors-son JT, Sigurdsson A, et al. 2008. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40: 1307-1312.
31. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. 2006. Myc influences global chromatin structure. EMBO J 25: 2723-2734.
32. Konsavage WM Jr, Jin G, Yochum GS. 2012. The Myc 3' Wnt-responsive element regulates homeostasis and regeneration in the mouse intestinal tract. Mol Cell Biol 32: 3891-3902.
33. Lazo PA, Lee JS, Tsichlis PN. 1990. Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in rat T-cell lymphomas. Proc Natl Acad Sci 87: 170-173.
34. Liu J, Levens D. 2006. Making myc. Curr Top Microbiol Immunol 302: 1-32.
35. Meyer KB, Maia AT, O'Reilly M, Ghoussaini M, Prathalin-gam R, Porter-Gill P, Ambs S, Prokunina-Olsson L, Carroll J, Ponder BA. 2011. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet 7: e1002165.
36. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, et al. 2013. The UCSC Genome Browser database: Extensions and updates 2013. Nucleic Acids Res 41: D64-D69.
37. Miele A, Dekker J. 2008. Long-range chromosomal interactions and gene regulation. Mol Biosyst 4: 1046-1057.
38. Muller J, Kassis JA. 2006. Polycomb response elements and targeting ofPolycomb group proteins in Drosophila. Curr Opin Genet Dev 16: 476-484.
39. Neiman PE, Ruddell A, Jasoni C, Loring G, Thomas SJ, Brandvold KA, Lee R, Burnside J, Delrow J. 2001. Analysis of gene expression during myc oncogene-induced lym-phomagenesis in the bursa of Fabricius. Proc Natl Acad Sci 98: 6378-6383.
40. Nishikura K, ar-Rushdi A, Erikson J, Watt R, Rovera G, Croce CM. 1983. Differential expression of the normal and of the translocated human c-myc oncogenes in B cells. Proc Natl Acad Sci 80: 4822-4826.
41. Patel JH, McMahon SB. 2007. BCL2 is a downstream effector of MIZ-1 essential for blocking c-MYC-induced apoptosis. JBiol Chem 282: 5-13.
42. Penn LJZ, Brooks MW, Laufer EM, Littlewood TD, Morgen-stern JP, Evan GI, Lee WMF, Land H. 1990. Domains of human c-Myc protein required for autosuppression and cooperation with ras oncogenes are overlapping. Mol Cell Biol 10: 4961-4966.
43. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, et al. 2009a. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41: 882-884.
44. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, et al. 2009b. Evaluation ofthe 8q24 prostate cancer risk locus and MYC expression. Cancer Res 69: 5568-5574.
45. Sears RC. 2004. The life cycle of C-myc: From synthesis to degradation. Cell Cycle 3: 1133-1137.
46. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J. 2001. TGFb influences Myc, Miz-1, and Smad to control the CDK inhibitor pp15INK4b. Nat Cell Biol 3: 400-408.
47. Simon JA, Kingston RE. 2009. Mechanisms of polycomb gene silencing: Knowns and unknowns. Nat Rev Mol Cell Biol 10: 697-708.
48. Smith E, Shilatifard A. 2010. The chromatin signaling pathway: Diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell 40: 689-701.
49. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Kar-sunky H, Moroy T, Bartek J, Massague J, Hanel F, et al. 2001. Repression ofp15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 3: 392-399.
50. Sur IK, Hallikas O, Vaharautio A, Yan J, Turunen M, Enge M, Taipale M, Karhu A, Aaltonen LA, Taipale J. 2012. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science 338: 1360-1363.
51. Tolhuis B, Palstra RJ, Splinter E, Grosveld F, de Laat W. 2002. Looping and interaction between hypersensitive sites in the active i-globin locus. Mol Cell 10: 1453-1465.
52. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, et al. 2007. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39: 984-988.
53. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanha-ranta S, Kivioja T, Bjorklund M, Wei G, Yan J, Niittymaki I, et al. 2009. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41: 885-890.
54. Van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, et al. 2002. The -catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250.
55. Wokolorczyk D, Gliniewicz B, Sikorski A, Zlowocka E, Ma-sojc B, Debniak T, Matyjasik J, Mierzejewski M, Medrek K, Oszutowska D, et al. 2008. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 68: 9982-9986.
56. Wood AJ, Severson AF, Meyer BJ. 2010. Condensin and co-hesin complexity: The expanding repertoire offunctions. Nat Rev Genet 11: 391-404.
57. Wright JB, Brown SJ, Cole MD. 2010. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 30: 1411-1420.
58. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, et al. 2007. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39:645-649.
59. Yeager M, Xiao N, Hayes RB, Bouffard P, Desany B, Burdett L, Orr N, Matthews C, Qi L, Crenshaw A, et al. 2008. Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet 124: 161-170.